Page 47 - Lipids News Today

High levels of high-density lipoprotein cholesterol is associated with a higher risk for fracture among older adults, a cohort study suggests.

Rapid tests are as reliable and accurate as those carried out by healthcare workers, experts say. Both tests are essential to increasing the rate of diagnosis.

Target achievement was lower among younger patients, particularly those under age 40 years.

Results from a crossover subgroup of 92 patients in ORION-3 documented evolocumabs greater LDL-lowering efficacy compared with inclisiran.

Patients achieve a reduction in systolic blood pressure of >15 mm Hg for as long as 8 weeks after administration of a single dose of zilebesiran.

A large dual-method Danish population study identified high LDL triglyceride levels as a risk marker for atherosclerotic cardiovascular disease.

After years of controversy, both skeptics and proponents of the REDUCE-IT study findings agree that a new trial may be desirable, but unlikely to happen.

Maricopa County’s ozone levels are getting worse, harming the health of its 4.5 million residents and threatening to cost the region billions of dollars in the coming years.

A readjudication of mortality data from the FOURIER trial by outside researchers concludes CV death was higher with evolocumab than originally reported. But FOURIER trialists stand by their conclusions.

Using the latest technologies-;including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells-;researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD).